We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Centogene NV (CNTG) NPV

Sell:$1.55 Buy:$1.62 Change: $0.11 (7.28%)
Market closed |  Prices as at close on 9 August 2022 | Switch to live prices |
Change: $0.11 (7.28%)
Market closed |  Prices as at close on 9 August 2022 | Switch to live prices |
Change: $0.11 (7.28%)
Market closed |  Prices as at close on 9 August 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Centogene BV is a Germany-based company engaged in the rare disease market. It focuses on transforming clinical, genetic and biochemical data into medical solutions for patients, physicians and pharmaceutical companies. The Company provides the full spectrum of methods and technology for human genetics analysis. It develops a rare disease platform based on its real-world data repository with over 2.0 billion weighted data points from over 450,000 patients representing around 115 different, which includes epidemiologic, phenotypic and genetic data that reflects a global population, as well as a biobank of patients’ blood samples. In addition, it is active in the research and development products for human genetics. The Company operates in Germany and the United States.

Contact details

Am Strande 7
+49 (30) 213000325

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$34.08 million
Shares in issue:
22.57 million
US dollar

Key personnel

  • Peer Schatz
    Independent Chairman of the Supervisory Board
  • Kim Stratton
    Chief Executive Officer, Managing Director, Member of the Management Board
  • Andreas Busch
    Vice Chairman of the Supervisory Board
  • Jose Rios
    Interim Chief Financial Officer
  • Nathalie Daste
    Chief Human Resource Officer
  • Volkmar Weckesser
    Chief Information Officer, Member of the Management Board
  • Patrice Denefle
    Chief Scientific Officer
  • Peter Bauer
    Chief Genomic Officer
  • Maximilian Schmid
    Chief Commercial Officer – Diagnostics
  • Florian Vogel
    Chief Process Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.